Drug intelligence / Profile preview

eseba-vec + pembrolizumab

Development stage: Unknown
Lead developer: NeoTrail Therapeutics
Modality: Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

eseba-vec + pembrolizumab (formerly HB-200 + pembrolizumab) is an investigational combination immunotherapy consisting of eseba-vec (HB-200) and the anti-PD-1 monoclonal antibody pembrolizumab. Eseba-vec is an arenavirus-based immunotherapy platform comprising two replicating, attenuated arenavirus vectors: HB-201 (derived from lymphocytic choriomeningitis virus) and HB-202 (derived from Pichinde virus). These vectors are engineered to express a non-oncogenic human papillomavirus type 16 (HPV16) E7/E6 fusion protein, designed to induce robust tumor-specific CD8+ T-cell responses against HPV16-positive tumors. Pembrolizumab acts as a checkpoint inhibitor to block the PD-1/PD-L1 pathway, thereby preventing T-cell inhibition and enhancing the vaccine-induced anti-tumor immune response. The combination is being evaluated in clinical trials for the treatment of patients with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma.

Other names: HB-200 + KeytrudaHB-200 + pembrolizumabHB-200 plus pembrolizumabHB200 plus pembrolizumabHB 200 plus pembrolizumabHB-201/HB-202 + pembrolizumabHB-202/HB-201 + pembrolizumabeseba-vec + Keytrudaeseba-vec + pembrolizumabeseba-vec plus pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)

Beyond the preview

Go deeper on eseba-vec + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eseba-vec + pembrolizumab.